Presbia PLC (NASDAQ:LENS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company’s product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. “

Separately, Rodman & Renshaw assumed coverage on Presbia PLC in a research report on Tuesday, May 10th. They set a “buy” rating and a $14.00 price target on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Presbia PLC (NASDAQ:LENS) traded up 2.25% during midday trading on Tuesday, reaching $4.09. The company had a trading volume of 2,794 shares. The company’s market capitalization is $54.55 million. Presbia PLC has a 12-month low of $2.94 and a 12-month high of $6.89. The stock has a 50-day moving average price of $4.30 and a 200 day moving average price of $4.51.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

5 Day Chart for NASDAQ:LENS

Get a free copy of the Zacks research report on Presbia PLC (LENS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with's FREE daily email newsletter.